NASDAQ:FLGT - Nasdaq - US3596641098 - Common Stock - Currency: USD
16.46
-0.17 (-1.02%)
The current stock price of FLGT is 16.46 USD. In the past month the price decreased by -2.89%. In the past year, price decreased by -31.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
DVA | DAVITA INC | 14.99 | 11.68B | ||
HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
CHE | CHEMED CORP | 23.84 | 8.18B | ||
CRVL | CORVEL CORP | 25.97 | 5.57B | ||
OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
GH | GUARDANT HEALTH INC | N/A | 5.30B |
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,184 full-time employees. The company went IPO on 2016-09-28. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The firm also offers next-generation sequencing (NGS) services.
FULGENT GENETICS INC
4399 Santa Anita Ave
El Monte CALIFORNIA 91780 US
CEO: Ming Hsieh
Employees: 1184
Company Website: https://www.fulgentgenetics.com/
Investor Relations: https://fulgentgenetics.gcs-web.com
Phone: 16263500537
The current stock price of FLGT is 16.46 USD. The price decreased by -1.02% in the last trading session.
The exchange symbol of FULGENT GENETICS INC is FLGT and it is listed on the Nasdaq exchange.
FLGT stock is listed on the Nasdaq exchange.
9 analysts have analysed FLGT and the average price target is 26.86 USD. This implies a price increase of 63.18% is expected in the next year compared to the current price of 16.46. Check the FULGENT GENETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FULGENT GENETICS INC (FLGT) has a market capitalization of 503.51M USD. This makes FLGT a Small Cap stock.
FULGENT GENETICS INC (FLGT) currently has 1184 employees.
FULGENT GENETICS INC (FLGT) has a support level at 16.14 and a resistance level at 16.59. Check the full technical report for a detailed analysis of FLGT support and resistance levels.
The Revenue of FULGENT GENETICS INC (FLGT) is expected to decline by -0.58% in the next year. Check the estimates tab for more information on the FLGT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FLGT does not pay a dividend.
FULGENT GENETICS INC (FLGT) will report earnings on 2025-02-28, before the market open.
The PE ratio for FULGENT GENETICS INC (FLGT) is 22.55. This is based on the reported non-GAAP earnings per share of 0.73 and the current share price of 16.46 USD. Check the full fundamental report for a full analysis of the valuation metrics for FLGT.
The outstanding short interest for FULGENT GENETICS INC (FLGT) is 5.05% of its float. Check the ownership tab for more information on the FLGT short interest.
ChartMill assigns a fundamental rating of 4 / 10 to FLGT. The financial health of FLGT is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months FLGT reported a non-GAAP Earnings per Share(EPS) of 0.73. The EPS increased by 162.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -13.37% | ||
ROE | -14.49% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to FLGT. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 181.27% and a revenue growth -0.58% for FLGT